559 related articles for article (PubMed ID: 12414524)
1. Aldosterone-induced inflammation in the rat heart : role of oxidative stress.
Sun Y; Zhang J; Lu L; Chen SS; Quinn MT; Weber KT
Am J Pathol; 2002 Nov; 161(5):1773-81. PubMed ID: 12414524
[TBL] [Abstract][Full Text] [Related]
2. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.
Sun Y; Zhang J; Lu L; Bedigian MP; Robinson AD; Weber KT
J Lab Clin Med; 2004 Jan; 143(1):41-51. PubMed ID: 14749684
[TBL] [Abstract][Full Text] [Related]
3. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface.
Ahokas RA; Warrington KJ; Gerling IC; Sun Y; Wodi LA; Herring PA; Lu L; Bhattacharya SK; Postlethwaite AE; Weber KT
Circ Res; 2003 Nov; 93(10):e124-35. PubMed ID: 14576195
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
[TBL] [Abstract][Full Text] [Related]
5. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade.
Ramires FJ; Sun Y; Weber KT
J Mol Cell Cardiol; 1998 Mar; 30(3):475-83. PubMed ID: 9515025
[TBL] [Abstract][Full Text] [Related]
6. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling.
Pu Q; Neves MF; Virdis A; Touyz RM; Schiffrin EL
Hypertension; 2003 Jul; 42(1):49-55. PubMed ID: 12782645
[TBL] [Abstract][Full Text] [Related]
7. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone.
Brilla CG; Zhou G; Matsubara L; Weber KT
J Mol Cell Cardiol; 1994 Jul; 26(7):809-20. PubMed ID: 7966349
[TBL] [Abstract][Full Text] [Related]
8. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.
Rocha R; Martin-Berger CL; Yang P; Scherrer R; Delyani J; McMahon E
Endocrinology; 2002 Dec; 143(12):4828-36. PubMed ID: 12446610
[TBL] [Abstract][Full Text] [Related]
9. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
Min LJ; Mogi M; Iwanami J; Li JM; Sakata A; Fujita T; Tsukuda K; Iwai M; Horiuchi M
Cardiovasc Res; 2007 Dec; 76(3):506-16. PubMed ID: 17706954
[TBL] [Abstract][Full Text] [Related]
10. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase.
Johar S; Cave AC; Narayanapanicker A; Grieve DJ; Shah AM
FASEB J; 2006 Jul; 20(9):1546-8. PubMed ID: 16720735
[TBL] [Abstract][Full Text] [Related]
11. [Effects of angiotensin II and aldosterone on NF-kappaB binding activity in hepatic stellate cells].
Li X; Meng Y; Jiang B; Yang XS; Wang WW; Guo D; Lai ZS; Zhang ZS
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(6):374-80. PubMed ID: 15854525
[TBL] [Abstract][Full Text] [Related]
12. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone.
Lacolley P; Labat C; Pujol A; Delcayre C; Benetos A; Safar M
Circulation; 2002 Nov; 106(22):2848-53. PubMed ID: 12451013
[TBL] [Abstract][Full Text] [Related]
13. Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone.
Thomas M; Vidal A; Bhattacharya SK; Ahokas RA; Sun Y; Gerling IC; Weber KT
Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2361-6. PubMed ID: 17616752
[TBL] [Abstract][Full Text] [Related]
14. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
[TBL] [Abstract][Full Text] [Related]
15. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
Shibata S; Nagase M; Yoshida S; Kawachi H; Fujita T
Hypertension; 2007 Feb; 49(2):355-64. PubMed ID: 17200434
[TBL] [Abstract][Full Text] [Related]
16. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.
Brilla CG; Matsubara LS; Weber KT
J Mol Cell Cardiol; 1993 May; 25(5):563-75. PubMed ID: 8377216
[TBL] [Abstract][Full Text] [Related]
17. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
[TBL] [Abstract][Full Text] [Related]
18. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
19. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype.
Gerling IC; Sun Y; Ahokas RA; Wodi LA; Bhattacharya SK; Warrington KJ; Postlethwaite AE; Weber KT
Am J Physiol Heart Circ Physiol; 2003 Aug; 285(2):H813-21. PubMed ID: 12860567
[TBL] [Abstract][Full Text] [Related]
20. Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone.
Nehme J; Mercier N; Labat C; Benetos A; Safar ME; Delcayre C; Lacolley P
J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):31-9. PubMed ID: 17083071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
